Sana Health
Military Operational Medicine funded for PTSD, Adjustment Disorder and Pain and Sleep (over $5m). 3 trials in progress. Sana Health is an FDA Breakthrough Designated Device, currently in front of the FDA for Neuropathic Pain as a de novo - expecting to be on market Q4 2025. Sana is a wearable audiovisual neuromodulation device, that provides anxiety and pain relief, and sleep on demand. $25m raised to date, and in the middle of a Series A extension SAFE note round.
Industries
Nr. of Employees
small (1-50)
Sana Health is currently seeking investment
Sana Health is seeking a series-a investment in the range of 1m-5m
Awards
Management of Post-Traumatic Stress Disorder Using Novel Audio-Visual Stimulation Device
Funding (ceiling)
$3,775,148.77
Award Year
2021
Patents
Non-pharmaceutical systems and methods of treating the symptoms of fibromyalgia
2024-09-03 • US-12076496-B2
View DetailsNon-pharmaceutical systems and methods of treating the symptoms of fibromyalgia
2022-12-13 • US-11524135-B2
View Details
Non-pharmaceutical systems and methods of treating the symptoms of fibromyalgia
2024-09-03 • US-12076496-B2
View DetailsNon-pharmaceutical systems and methods of treating the symptoms of fibromyalgia
2022-12-13 • US-11524135-B2
View DetailsProducts
Wearable neuromodulation device
A battery-powered, non-invasive wearable intended to deliver coordinated rhythmic visual and auditory stimulation for enhanced rest and investigational therapeutic use. The device is currently used in clinical studies and is not available for general sale.
Wearable neuromodulation device
A battery-powered, non-invasive wearable intended to deliver coordinated rhythmic visual and auditory stimulation for enhanced rest and investigational therapeutic use. The device is currently used in clinical studies and is not available for general sale.
Expertise Areas
- Neuromodulation (non-invasive light + sound)
- Clinical trial design and management (RCTs)
- Regulatory strategy and FDA interactions
- Digital health and mobile therapeutics
Key Technologies
- Wearable neuromodulation (coordinated light and sound)
- Adaptive AI feedback loops
- Mobile app integration with Bluetooth connectivity
- Blinded randomized controlled trial methodology
Key People
Featured In Technology Showcase
Sana Health publishes first peer-reviewed article exploring the effectiveness of Sana device in managing PTSD in MTEC/MOMRP/VA study
Researchers found that combining the Sana Device with standard PTSD treatments significantly improved symptoms, anxiety, depression, and quality of life in veterans, outperforming treatment alone. This non-invasive, drug-free technology offers a promising mental health tool. A $3.4M follow-up study is underway, with broader trials and FDA approval efforts in progress.
Investors
Noetic Fund
$4,200,000 funded.
Announced on 2021-09-01.
Venture Round - Sana Health
Announced on 2021-05-26.
Seed Round - Sana Health
Announced on 2020-11-01.
MassChallenge
Announced on 2020-10-21.
Seed Round - Sana Health
$5,800,000 funded.
Announced on 2020-08-04.
Grey House Partners
$1,800,000 funded.
Announced on 2020-06-01.
Noetic Fund
$4,200,000 funded.
Announced on 2021-09-01.
Venture Round - Sana Health
Announced on 2021-05-26.
Seed Round - Sana Health
Announced on 2020-11-01.
MassChallenge
Announced on 2020-10-21.
Seed Round - Sana Health
$5,800,000 funded.
Announced on 2020-08-04.
Grey House Partners
$1,800,000 funded.
Announced on 2020-06-01.
News & Updates
Funded by the Department of Defense for PTSD
Sana Health has received funding from the Department of Defense to support its initiatives related to PTSD.
Pivotal Neuropathic Pain data submitted to the FDA for market approval
Sana Health has submitted pivotal data to the FDA for market approval regarding its device's effectiveness in treating neuropathic pain.
Funded by the Department of Defense for PTSD
Sana Health has received funding from the Department of Defense to support its initiatives related to PTSD.
Pivotal Neuropathic Pain data submitted to the FDA for market approval
Sana Health has submitted pivotal data to the FDA for market approval regarding its device's effectiveness in treating neuropathic pain.